CXCL12 and neoplasm: Thus, strategies to eliminate stoma components, such as CAFs, have been developed, including the use of AMD3100 to deplete the CXCL12+ FAP+ CAF population, which results in a marked infiltration of T cells into the tumor and an increase in the effectiveness of anti-PDL1 therapy [240].